Whitney Melroy-Greif concentrates her work on genetic engineering, molecular biology, and cellular biology for the biotechnology and pharmaceutical industries. Whitney has 6 years of experience working in patent prosecution, and currently focuses on patent prosecution of a wide variety of technologies including cancer therapeutics for small biotechnology companies. Prior to private practice, she was a postdoctoral fellow at The Scripps Research Institute. Before graduate school, she worked as a research associate in the hybridoma laboratory at Santa Cruz Biotechnology Inc. 

Thought Leadership

  • Co-Author, “No Evidence that Schizophrenia Candidate Genes are More Associated with Schizophrenia than Non-Candidate Genes,” Biol Psychiatry, Nov 2017
  • First Author, “Genome-Wide Association Study of Post-Traumatic Stress Disorder in Two High-Risk Populations,” Twin Res Hum Genet, June 2017
  • First Author, “Examination of the Involvement of Cholinergic-Associated Genes in Nicotine Behaviors in European and African Americans,” Nicotine Tob Res, April 2017
  • Co-Author, “Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts,” Behav Genet, March 2016 
  • First Author, “Nicotinic acetylcholine receptors: upregulation, age-related effects, and associations with drug use,” Genes Brain Behav, January 2016
  • First Author, “Examination of genetic variation in GABRA2 with conduct disorder and alcohol abuse and dependence in a longitudinal study,” Behav Genet, July 2014